Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE versus POTASSIUM CHLORIDE 0 11 IN DEXTROSE 10 AND SODIUM CHLORIDE 0 45 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE versus POTASSIUM CHLORIDE 0 11 IN DEXTROSE 10 AND SODIUM CHLORIDE 0 45 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE vs POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
Potassium chloride provides potassium ions, essential for maintaining cellular membrane potential, nerve impulse transmission, and muscle contraction. Dextrose provides a source of glucose for cellular metabolism, and sodium chloride provides sodium and chloride ions for electrolyte balance.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
Intravenous infusion. Dose based on individual electrolyte and fluid requirements, typically 500-1000 mL/hour for correction of hypokalemia; maximum infusion rate: 10 mEq potassium per hour via peripheral line, 20 mEq/hour via central line. Potassium concentration should not exceed 40 mEq/L peripherally or 80 mEq/L centrally.
None Documented
Clinical Note
moderateMagnesium sulfate + Gatifloxacin
"The serum concentration of Gatifloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Rosoxacin
"The serum concentration of Rosoxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Levofloxacin
"The serum concentration of Levofloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateNone Documented
Terminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Potassium (plasma): ~1-1.5 hours; total body potassium half-life ~10-12 hours. Clinically, steady state reached in 2-3 days with continuous infusion.
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Potassium: primarily renal (90% excreted in urine); sodium: renal (90-95%); chloride: renal; dextrose: metabolized to CO2 and water. Less than 1% fecal elimination.
Category C
Category A/B
Electrolyte
Electrolyte
Magnesium sulfate + Trovafloxacin
"The serum concentration of Trovafloxacin can be decreased when it is combined with Magnesium sulfate."